ATE89263T1 - Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. - Google Patents

Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Info

Publication number
ATE89263T1
ATE89263T1 AT91400526T AT91400526T ATE89263T1 AT E89263 T1 ATE89263 T1 AT E89263T1 AT 91400526 T AT91400526 T AT 91400526T AT 91400526 T AT91400526 T AT 91400526T AT E89263 T1 ATE89263 T1 AT E89263T1
Authority
AT
Austria
Prior art keywords
lower alkyl
aryl
production
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT91400526T
Other languages
English (en)
Inventor
Jean Andrieux
Raymond Houssin
Said Yous
Beatrice Guardiola
Daniel Lesieur
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of ATE89263T1 publication Critical patent/ATE89263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT91400526T 1990-02-27 1991-02-27 Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. ATE89263T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9002393A FR2658818B1 (fr) 1990-02-27 1990-02-27 Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP91400526A EP0447285B1 (de) 1990-02-27 1991-02-27 Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE89263T1 true ATE89263T1 (de) 1993-05-15

Family

ID=9394160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91400526T ATE89263T1 (de) 1990-02-27 1991-02-27 Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Country Status (17)

Country Link
US (3) US5194614A (de)
EP (1) EP0447285B1 (de)
JP (1) JP2624901B2 (de)
AT (1) ATE89263T1 (de)
AU (1) AU634350B2 (de)
CA (1) CA2036876C (de)
DE (2) DE69100079T2 (de)
DK (1) DK0447285T3 (de)
ES (1) ES2059069T4 (de)
FR (1) FR2658818B1 (de)
HK (1) HK57197A (de)
IE (1) IE66011B1 (de)
LU (1) LU91587I2 (de)
NL (1) NL300396I1 (de)
OA (1) OA09482A (de)
PT (1) PT96890B (de)
ZA (1) ZA911403B (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2713636B1 (fr) * 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
HUT75128A (en) 1994-03-30 1997-04-28 Ciba Geigy Ag Screening method using the rzr receptor family
US5856124A (en) 1994-06-17 1999-01-05 The General Hospital Corporation DNA encoding high-affinity melatonin receptors
US7081349B1 (en) 1994-06-17 2006-07-25 The General Hospital Corporation High-affinity melatonin receptor and uses thereof
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US6235789B1 (en) 1994-09-12 2001-05-22 Takeda Chemical Industries, Ltd. Benzocycloalkene compounds, their production and use
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
US5998461A (en) * 1994-10-21 1999-12-07 Adir Et Compagnie Tricyclic amide compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6071946A (en) * 1994-10-21 2000-06-06 Adir Et Compagnie Tricyclic urea compounds
FR2726268B1 (fr) * 1994-10-26 1996-12-06 Adir Nouvelles o-arylmethyl n-(thio)acyl hydroxylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent
US5530012A (en) * 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
FR2729147A1 (fr) * 1995-01-11 1996-07-12 Adir Nouveaux composes (hetero) cycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5661186A (en) * 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides
FR2734814B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734816B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux aryl (alkyl) propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734815B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
WO1997001539A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
EP0848699B1 (de) * 1995-07-26 2001-10-24 Takeda Chemical Industries, Ltd. Benzocycloalken-verbindungen mit bindungsaffinität an den melatonin-rezeptor, ihre herstellung und verwendung
FR2737725B1 (fr) * 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
FR2741799B1 (fr) * 1995-12-04 1998-01-02 Oreal Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue
CA2240395A1 (en) * 1995-12-13 1997-06-19 David Kent Herron Naphthyl acetamides as spla2 inhibitors
AU1149797A (en) * 1995-12-13 1997-07-03 Eli Lilly And Company Naphthyl glyoxamides as spla2 inhibitors
US6090850A (en) * 1996-02-05 2000-07-18 Eli Lilly And Company Naphthyl glyoxamides as SPLA2 inhibitors
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
IL129999A (en) * 1996-12-10 2004-06-20 Bristol Myers Squibb Co Melatonergic agents which are benzodioxole, benzopuran, dihydrobenzopuran and benzodioxane
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
JP2002513412A (ja) * 1997-04-14 2002-05-08 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
AU6896298A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
AU6896398A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
FR2763335B1 (fr) * 1997-05-16 2000-11-24 Adir Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6028112A (en) * 1997-05-23 2000-02-22 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
FR2771739B1 (fr) * 1997-11-28 2001-04-20 Adir Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) * 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU6748000A (en) * 1999-07-22 2001-02-13 General Hospital Corporation, The Method for identifying compounds which modulate circadian rhythm
DE60044134D1 (de) 1999-08-26 2010-05-20 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
JP2001288138A (ja) * 2000-04-04 2001-10-16 Kanto Denka Kogyo Co Ltd 含フッ素α，β−不飽和カルボン酸の製造方法
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
FR2853649B1 (fr) * 2003-04-09 2006-07-14 Servier Lab Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2857593B1 (fr) * 2003-07-18 2005-10-14 Servier Lab Composition pharmaceutique orodispersible d'un compose antithrombotique
FR2866337B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'aglomelatine
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
US7498465B2 (en) 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US7645905B2 (en) 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
KR100904116B1 (ko) * 2005-08-03 2009-06-24 르 라보레또레 쎄르비에르 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US7635721B2 (en) 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
FR2890563B1 (fr) 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2890564B1 (fr) 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
CN101161638B (zh) * 2006-10-13 2010-09-29 北京德众万全药物技术开发有限公司 一种新的阿戈美拉汀重要中间体的制备方法
FR2908995B1 (fr) 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
FR2908994B1 (fr) * 2006-11-24 2009-04-03 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire
JP4642134B2 (ja) * 2007-05-01 2011-03-02 コンサート ファーマシューティカルズ インコーポレイテッド ナフチル（エチル）アセトアミド
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
JP2009013074A (ja) * 2007-06-30 2009-01-22 Lab Servier 全般性不安障害の処置を目的とする医薬を得るためのアゴメラチンの使用
FR2919606B1 (fr) 2007-08-03 2010-09-17 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine.
DE102007039743A1 (de) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit Alkohol(en) und Melatonin/Agomelatin
DE102007039745A1 (de) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit Pflegestoff(en) und Melatonin/Agomelatin
DE102007039741A1 (de) * 2007-08-22 2009-02-26 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit Tensid(en) und Melatonin/Agomelatin
FR2923482B1 (fr) 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101429124B (zh) * 2007-11-09 2011-10-26 上海医药工业研究院 一种(7-甲氧基-1-萘基)乙酸乙酯的合成方法
WO2009097144A1 (en) * 2008-01-30 2009-08-06 The Trustees Of Columbia University In The City Of New York Molecular probes for pet-imaging of dopamine neurotransmission and neuroendocrine processes in vivo
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
CN101638376B (zh) 2008-07-29 2011-04-27 江苏恩华药业股份有限公司 阿戈美拉汀的制备方法及其中间体
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
FR2934855B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2934859B1 (fr) 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
EP2319827A1 (de) 2009-11-09 2011-05-11 Ratiopharm GmbH Verfahren zur Herstellung der polymorphen Form I von Agomelatin
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102146046B (zh) * 2010-02-05 2013-07-03 天津市汉康医药生物技术有限公司 一种n-[2-(7-甲氧基-1-萘基)乙基]乙酰胺新的制备方法
FR2956031B1 (fr) 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
EP2558440B1 (de) 2010-04-15 2016-11-16 ratiopharm GmbH Verfahren zur herstellung einer polymorphen form i von agomelatin
EP2576540B1 (de) 2010-05-26 2019-09-04 Sunovion Pharmaceuticals Inc. Hezeroarylverbindungen und verfahren zur verwendung davon
CN102276492B (zh) * 2010-06-08 2013-04-10 上海医药工业研究院 阿戈美拉汀中间体及其制备方法
EP2580183B1 (de) 2010-06-10 2014-07-23 Gador S.A. Neues verfahren zur herstellung von n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamid
CN102229541A (zh) * 2010-09-17 2011-11-02 福建广生堂药业有限公司 阿戈美拉汀n-[2-(7-甲氧基萘-1-基)乙基]乙酰胺的制备方法
CN102452951B (zh) * 2010-10-25 2014-02-19 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102452952A (zh) * 2010-11-03 2012-05-16 天津药物研究院 一种高纯度的i型阿戈美拉汀晶体制备方法
WO2012070025A1 (en) 2010-11-26 2012-05-31 Cadila Pharmaceuticals Ltd Process for the preparation of agomelatine
CN102531956B (zh) * 2010-12-21 2014-07-09 浙江九洲药业股份有限公司 用于制备阿戈美拉汀的中间体及相关制备方法
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
FR2970000B1 (fr) 2011-01-05 2013-01-04 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2970001B1 (fr) * 2011-01-05 2013-01-04 Servier Lab Nouveau procede de synthese de l'agomelatine
CZ303787B6 (cs) 2011-01-21 2013-05-02 Zentiva, K.S. Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice
CZ303789B6 (cs) * 2011-01-21 2013-05-02 Zentiva, K.S. Zpusob prípravy krystalové formy agomelatinu a jeho pouzití
CZ303788B6 (cs) * 2011-01-21 2013-05-02 Zentiva, K.S. Zpusob prípravy krystalové formy agomelatinu
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
CN102206864B (zh) * 2011-04-13 2012-10-03 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法
PH12012000132A1 (en) 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
ITMI20111078A1 (it) * 2011-06-15 2012-12-16 Laboratorio Chimico Int Spa Procedimento per la preparazione di forme cristalline dell?agomelatina e nuovo polimorfo
WO2013013060A1 (en) * 2011-07-19 2013-01-24 Lycus, Llc Agomelatine derivatives
IN2014CN00348A (de) 2011-08-03 2015-04-03 Laboratorio Chimico Int Spa
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2562151A1 (de) 2011-08-25 2013-02-27 Dr. Reddy's Laboratories Ltd. Prozesse zur Herstellung von Agomelatin und seine Zwischenstoffe
WO2013054273A2 (en) 2011-10-11 2013-04-18 Ranbaxy Laboratories Limited Process for the preparation of agomelatine
WO2013063289A1 (en) * 2011-10-25 2013-05-02 Lycus Llc Pharmaceutical compositions for treating pain
CN102432490A (zh) * 2011-11-02 2012-05-02 江西施美制药有限公司 一种阿戈美拉汀晶型d及其制备方法
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
EP2785681A1 (de) 2011-12-01 2014-10-08 Ranbaxy Laboratories Limited Verfahren zur herstellung von agomelatin
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
US9409857B2 (en) * 2012-05-14 2016-08-09 Shanghai Righthand Pharmtech, Co., Ltd. Agomelatine sulfuric acid complex, and preparation method and application thereof
WO2014001939A1 (en) * 2012-06-30 2014-01-03 Alembic Pharmaceuticals Limited Process for preparation of agomelatine and crystalline form i thereof
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
EP2884275A4 (de) * 2012-07-10 2016-04-13 Astellas Pharma Inc Pharmazeutische zusammensetzung zur behandlung oder prävention von stressbedingter harninkontinenz oder mischinkontinenz sowie verfahren zum screening von verbindungen zum einbringen in diese pharmazeutische zusammensetzung
EP2872129B1 (de) 2012-07-16 2017-03-08 ratiopharm GmbH Komplex aus agomelatin und cyclodextrin
ITMI20121444A1 (it) 2012-08-27 2014-02-28 Procos Spa Processo per la produzione di agomelatine
CN102911075A (zh) * 2012-09-29 2013-02-06 福建广生堂药业股份有限公司 一种阿戈美拉汀硫酸盐新晶型ⅰ及其制备方法
EP2921473B1 (de) * 2012-10-09 2017-09-27 Jiangxi Synergy Pharmaceutical Co. Ltd. 1-cyan-1-(7-methoxyl-1-naphtyl)-methanolesterverbindung sowie herstellungsverfahren und verwendung davon
EP2909166A4 (de) * 2012-10-22 2016-10-26 Symed Labs Ltd Prozesse zur herstellung von agomelatin mithilfe neuartiger zwischenstoffe
WO2014072998A1 (en) 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
ES2590908T3 (es) 2012-12-17 2016-11-24 Dr. Reddy's Laboratories Ltd. Cocristal de agomelatina con ácido fosfórico
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP2934502A1 (de) 2012-12-21 2015-10-28 Laboratorios Lesvi S.L. Verfahren zur herstellung von n-(2-(7-methoxy-1-naphthalenyl)ethyl)acetamid und feste formen davon
CN103073445A (zh) * 2012-12-21 2013-05-01 北京万全德众医药生物技术有限公司 阿戈美拉汀工艺杂质的制备方法
CN103073441A (zh) * 2012-12-27 2013-05-01 上海右手医药科技开发有限公司 合成（7-甲氧基-1-萘基）乙胺的新方法及其在合成阿戈美拉汀中的应用
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (de) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmazeutische Formulierungen, enthaltend Agomelatin in der Form des Co-Kristalls von Agomelatin mit organischer Säure
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
FR3014433B1 (fr) 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
US11479766B2 (en) * 2013-12-05 2022-10-25 New England Biolabs, Inc. Methods for labeling a population of RNA molecules
FR3014434B1 (fr) 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FR3014437B1 (fr) 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN104803882B (zh) * 2014-01-26 2017-02-01 江西同和药业股份有限公司 一种化合物及其制备方法和应用
KR101606395B1 (ko) 2014-02-05 2016-03-25 (주)국전약품 아고멜라틴의 제조방법
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
CN105193764A (zh) * 2014-05-30 2015-12-30 北大方正集团有限公司 一种阿戈美拉汀固体分散体及其制备方法
EP3075724B1 (de) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Feste form von agomelatin
FR3056211B1 (fr) 2016-09-19 2018-09-07 Servier Lab Nouveau procede de synthese de l'agomelatine
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
CN107353229B (zh) * 2017-08-08 2019-04-30 许昌恒生制药有限公司 一种阿戈美拉汀中间体的制备方法
EP3466923A1 (de) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Verfahren zur herstellung von agomelatin in kristalliner form
EP3466413A1 (de) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmazeutische zusammensetzung mit agomelatin und verfahren zur herstellung davon
WO2022022542A1 (zh) * 2020-07-28 2022-02-03 上海翰森生物医药科技有限公司 双环类衍生物调节剂、其制备方法和应用
JP2024519338A (ja) 2021-05-11 2024-05-10 ニューリム・ファーマシューティカルズ・リミテッド ２番染色体、２：１０７，５１０，０００－１０７，５４０，０００遺伝子座に一塩基多型を有する対象を診断および処置するための方法。
CN115872887B (zh) * 2022-12-30 2023-07-07 上海国创医药股份有限公司 一种阿戈美拉汀的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1188544A (en) * 1914-07-09 1916-06-27 Basf Ag Derivatives of 1-amino-7-naphthol.
US2516130A (en) * 1949-03-26 1950-07-25 Parke Davis & Co Naphthalene compounds
US3057919A (en) * 1961-02-17 1962-10-09 Dow Chemical Co N-(salicyl)-benzamide derivatives
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US3308157A (en) * 1964-08-07 1967-03-07 Colgate Palmolive Co N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides
US3625972A (en) * 1968-07-03 1971-12-07 Sterling Drug Inc N-phenylbenzanilides
US3689557A (en) * 1969-06-09 1972-09-05 American Home Prod Phenethylamides
US3871865A (en) * 1970-11-18 1975-03-18 Eugene G Teach Ether and sulfide meta-substituted anilides and their utility as herbicides
US3706796A (en) * 1970-11-25 1972-12-19 Monsanto Co Substituted amides
BE787381A (fr) * 1971-08-12 1973-02-09 Basf Ag Amides substitues de l'acide benzoique
DE2235597A1 (de) * 1972-07-20 1974-01-31 Boehringer Mannheim Gmbh 1-eckige klammer auf 3-(5,6,7,8tetrahydronaphth-1-yl-oxy) -propyl eckige klammer zu -piperazin-derivate und verfahren zu ihrer herstellung
US4169108A (en) * 1973-08-16 1979-09-25 Sterling Drug Inc. 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols
JPS53113033A (en) * 1977-03-14 1978-10-03 Tanabe Seiyaku Co Ltd Antihyperlipemics
GB2093837B (en) * 1981-03-02 1985-04-24 Abbott Lab Aminoalkyl subsituted 1,2,3,4-tetrahydronaphtalenes
GB8400964D0 (en) * 1984-01-13 1984-02-15 Sandoz Ltd Organic compounds
JPS6461447A (en) * 1987-08-28 1989-03-08 Nihon Iyakuhin Kogyo Co Ltd (+-)-or (+)-1-(2-n-substituted aminoethyl)-1-methyl-7-methoxy-1,2,3,4-tetrahydronaphthalene and production thereof
EP0413666B1 (de) * 1989-08-18 1994-04-13 Ciba-Geigy Ag Buttersäurederivate
AU6659090A (en) * 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
ES2059069T4 (es) 2012-03-13
AU634350B2 (en) 1993-02-18
NL300396I1 (nl) 2009-10-01
FR2658818B1 (fr) 1993-12-31
LU91587I2 (fr) 2009-09-22
IE910640A1 (en) 1991-08-28
ES2059069T3 (es) 1994-11-01
PT96890B (pt) 1998-07-31
US5194614A (en) 1993-03-16
HK57197A (en) 1997-05-09
EP0447285A1 (de) 1991-09-18
AU7137591A (en) 1991-08-29
DE122009000040I2 (de) 2011-01-13
CA2036876A1 (fr) 1991-08-28
DE69100079D1 (de) 1993-06-17
US5318994A (en) 1994-06-07
CA2036876C (fr) 1998-08-18
FR2658818A1 (fr) 1991-08-30
DE122009000040I1 (de) 2009-11-05
PT96890A (pt) 1991-10-31
EP0447285B1 (de) 1993-05-12
DK0447285T3 (da) 1993-08-16
ZA911403B (en) 1991-11-27
DE69100079T2 (de) 1993-12-09
IE66011B1 (en) 1995-11-29
OA09482A (fr) 1992-11-15
JP2624901B2 (ja) 1997-06-25
JPH0748331A (ja) 1995-02-21
US5225442A (en) 1993-07-06

Similar Documents

Publication Publication Date Title
ATE89263T1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE130604T1 (de) Neue arylethylaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE124047T1 (de) Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
ATE21699T1 (de) Verfahren zur herstellung von 2-penemverbindungen.
ATE14579T1 (de) Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
ATE19878T1 (de) Benzimidazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69129175D1 (de) 1-Methylcarbapenemderivate und Verfahren zu ihrer Herstellung
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
AT389108B (de) Neue pyridazinonderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE37533T1 (de) Derivate der 4-phenyl-4-oxo-buten-2-saeure, verfahren zu ihrer herstellung, medikamente und mischungen mit diesen derivaten.
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
ATE18667T1 (de) Aethenylimidazol-derivate, verfahren zu deren herstellung und deren pharmazeutische zusammensetzungen, bei deren herstellung verwendbare zwischenprodukte und verfahren zu deren herstellung.
ATE69448T1 (de) Chinolincarbonsaeure-derivate, diese enthaltende zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten.
ATE35133T1 (de) N-substituierte (bis(hydroxymethyl)-methyl>isochinolinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
ATE43575T1 (de) (4.2.0>-bicyclooctanderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE29251T1 (de) Aminopyridincarbonsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE27602T1 (de) Tryptaminderivate mit wirkung auf das kardiovaskulaere system und verfahren zu ihrer herstellung.
ATE95180T1 (de) Berbanderivate und ihre herstellung und pharmazeutische zubereitung.
ATE29133T1 (de) Troponon-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
ATE36154T1 (de) 4-phenylaminopyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.